AMENDMENTS TO ARTICLES OF ASSOCIATION OF BIOHIT OYJ COME INTO POWER TODAY
BIOHIT OYJ STOCK EXCHANGE RELEASE ON 14 MAY 2010 AT 02:10 PM
AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF BIOHIT OYJ COME INTO POWER TODAY
The amendments to the Articles of Association of Biohit Oyj, decided by the AGM
on 23 April 2010, have been registered and come into effect today, on 14 May
2010.
In accordance with the amendments, the term of Ainomaija Haarla, who was elected
as new member to the Board of Directors, begins today.
More information on the amendments made is available in the minutes of the
AGM and the stock exchange release on 26 April 2010 (see
www.biohit.com/investors).
Further information:
Jussi Heiniö
VP, Administration and Legal Affairs
Tel: +358-9-773 861
Email: jussi.heinio@biohit.com
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on
the global market. Biohit's operations are based on a goal-oriented and
long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of
the gastrointestinal tract.
Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions,
healthcare and industrial laboratories.
The diagnostics business comprises products and analysis systems for the early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic
stomachs.
The Biohit Group employs around 390 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA, as well as a representative office in
Singapore. Additionally, Biohit's products are sold by approximately 450
distributors in 70 countries.
Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small
cap/Healthcare since 1999.
Read more at www.biohit.com
